News

This therapy is designed for the treatment of multiple sclerosis (MS), a chronic neurodegenerative autoimmune disease. CAR T-cell therapy involves modifying a patient’s T cells to target and

This partnership covers drug-linker technology and CRDMO services right from discovery to commercialisation. WuXi XDC CEO Dr. Jimmy Li said, “IntoCell’s unique drug-linker technologies and our leading, open-access

This development is part of Galapagos’ strategy to transform into a new biotechnology enterprise with a robust research and development pipeline for treating disease immunology and oncology fields.

Received through the foundation’s Inflammatory Bowel Disease (IBD) Ventures programme, this payment is part of a priorly disclosed grant under research programme agreement with Giiant Pharma to support

In October this year, Lilly signed a definitive agreement for POINT Biopharma acquisition. POINT Biopharma focuses on developing radioligand treatments for cancer and has a pipeline of such

Designed based on the Ligand and Enhancer Assisted Delivery (LEAD) platform of SanegeneBio, SGB-3908 is currently in the investigational new drug application (IND)-enabling stage of development. Both Innovent

A HER3 targeting DXd antibody-drug conjugate (ADC), patritumab deruxtecan is intended for usage in patients with locally advanced or metastatic EGFR-mutated NSCLC, who have been treated with two

Currently, SLS009 is under evaluation in a Phase Ib/II trial for patients with r/r PTCL. The study, which is open-label and single-arm, plans to enrol up to 95

This marks Nefecon as the first FDA-approved treatment for IgAN. Nefecon is an oral, delayed-release formulation of budesonide, a corticosteroid with potent anti-inflammatory properties. The enteric-coated capsule approval